These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 9849963)
1. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Tagami T; Gu WX; Peairs PT; West BL; Jameson JL Mol Endocrinol; 1998 Dec; 12(12):1888-902. PubMed ID: 9849963 [TBL] [Abstract][Full Text] [Related]
2. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. Safer JD; Cohen RN; Hollenberg AN; Wondisford FE J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773 [TBL] [Abstract][Full Text] [Related]
3. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. Liu Y; Takeshita A; Misiti S; Chin WW; Yen PM Endocrinology; 1998 Oct; 139(10):4197-204. PubMed ID: 9751500 [TBL] [Abstract][Full Text] [Related]
4. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone. Tagami T; Jameson JL Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636 [TBL] [Abstract][Full Text] [Related]
5. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone. Ishii S; Yamada M; Satoh T; Monden T; Hashimoto K; Shibusawa N; Onigata K; Morikawa A; Mori M Mol Endocrinol; 2004 Jul; 18(7):1708-20. PubMed ID: 15131262 [TBL] [Abstract][Full Text] [Related]
6. A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone. Wu SY; Cohen RN; Simsek E; Senses DA; Yar NE; Grasberger H; Noel J; Refetoff S; Weiss RE J Clin Endocrinol Metab; 2006 May; 91(5):1887-95. PubMed ID: 16464943 [TBL] [Abstract][Full Text] [Related]
7. A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators. Collingwood TN; Rajanayagam O; Adams M; Wagner R; Cavaillès V; Kalkhoven E; Matthews C; Nystrom E; Stenlof K; Lindstedt G; Tisell L; Fletterick RJ; Parker MG; Chatterjee VK Proc Natl Acad Sci U S A; 1997 Jan; 94(1):248-53. PubMed ID: 8990194 [TBL] [Abstract][Full Text] [Related]
8. Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators. Lin KH; Wu YH; Chen SL Endocrinology; 2001 Feb; 142(2):653-62. PubMed ID: 11159836 [TBL] [Abstract][Full Text] [Related]
9. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity. Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. Jeyakumar M; Tanen MR; Bagchi MK Mol Endocrinol; 1997 Jun; 11(6):755-67. PubMed ID: 9171239 [TBL] [Abstract][Full Text] [Related]
12. A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation. Clifton-Bligh RJ; de Zegher F; Wagner RL; Collingwood TN; Francois I; Van Helvoirt M; Fletterick RJ; Chatterjee VK Mol Endocrinol; 1998 May; 12(5):609-21. PubMed ID: 9605924 [TBL] [Abstract][Full Text] [Related]
13. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential. Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988 [TBL] [Abstract][Full Text] [Related]
14. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Tagami T; Lutz WH; Kumar R; Jameson JL Biochem Biophys Res Commun; 1998 Dec; 253(2):358-63. PubMed ID: 9878542 [TBL] [Abstract][Full Text] [Related]
15. The thyroid hormone receptor variant alpha2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressors. Tagami T; Kopp P; Johnson W; Arseven OK; Jameson JL Endocrinology; 1998 May; 139(5):2535-44. PubMed ID: 9564869 [TBL] [Abstract][Full Text] [Related]
16. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT. Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777 [TBL] [Abstract][Full Text] [Related]
17. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation. Nomura Y; Nagaya T; Tsukaguchi H; Takamatsu J; Seo H Endocrinology; 1996 Oct; 137(10):4082-6. PubMed ID: 8828460 [TBL] [Abstract][Full Text] [Related]
18. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells. Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586 [TBL] [Abstract][Full Text] [Related]
19. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone. Ng L; Forrest D; Haugen BR; Wood WM; Curran T Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112 [TBL] [Abstract][Full Text] [Related]
20. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. Collingwood TN; Wagner R; Matthews CH; Clifton-Bligh RJ; Gurnell M; Rajanayagam O; Agostini M; Fletterick RJ; Beck-Peccoz P; Reinhardt W; Binder G; Ranke MB; Hermus A; Hesch RD; Lazarus J; Newrick P; Parfitt V; Raggatt P; de Zegher F; Chatterjee VK EMBO J; 1998 Aug; 17(16):4760-70. PubMed ID: 9707435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]